PDSB PDS Biotechnology Corp
Price (delayed)
$1.155
Market cap
$52.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$32.57M
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively
Highlights
PDS Biotechnology's EPS has increased by 26% YoY and by 12% QoQ
PDS Biotechnology's net income has increased by 12% YoY and by 7% from the previous quarter
The quick ratio is down by 41% YoY and by 10% from the previous quarter
The equity has contracted by 27% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of PDSB
Market
Valuations
Earnings
Shares outstanding
45.4M
Market cap
$52.43M
Enterprise value
$32.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$36.32M
Net income
-$37.61M
EBIT
-$36.32M
EBITDA
-$36.3M
Free cash flow
-$35.06M
Per share
Balance sheet
Liquidity
EPS
-$1.03
EPS diluted
-$1.03
Free cash flow per share
-$0.96
Book value per share
$0.51
Revenue per share
$0
TBVPS
$1.24
Total assets
$45.36M
Total liabilities
$26.35M
Debt
$21.83M
Equity
$19M
Working capital
$27.97M
Debt to equity
1.15
Current ratio
2.64
Quick ratio
2.44
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-66.2%
Return on equity
-137.9%
Return on invested capital
-360.3%
Return on capital employed
-128.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PDSB stock price
How has the PDS Biotechnology stock price performed over time
Intraday
6.94%
1 week
-6.85%
1 month
-13.16%
1 year
-68.95%
YTD
-29.14%
QTD
-2.94%
Financial performance
How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.32M
Net income
-$37.61M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 16% YoY and by 8% from the previous quarter
PDS Biotechnology's net income has increased by 12% YoY and by 7% from the previous quarter
Growth
What is PDS Biotechnology's growth rate over time
Valuation
What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
2.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 26% YoY and by 12% QoQ
The P/B is 49% lower than the last 4 quarters average of 4.2 and 47% lower than the 5-year quarterly average of 4.0
The equity has contracted by 27% YoY and by 14% from the previous quarter
Efficiency
How efficient is PDS Biotechnology business performance
PDS Biotechnology's ROIC has plunged by 50% YoY and by 2.9% from the previous quarter
The ROA is up by 4.1% YoY
Dividends
What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PDSB.
Financial health
How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 72% more than its total liabilities
The quick ratio is down by 41% YoY and by 10% from the previous quarter
PDSB's current ratio is down by 39% year-on-year and by 7% since the previous quarter
PDS Biotechnology's debt is 15% higher than its equity
The equity has contracted by 27% YoY and by 14% from the previous quarter
The debt to equity is up by 26% year-on-year and by 2.7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.